The IOV-COM-202 trial reported a 65.2% response rate and a 30.4% complete response rate for the Lifileucel and Pembrolizumab combination in frontline advanced melanoma. How do these results compare to current standard treatments, and what significance do they hold for future melanoma therapies?

With nearly all responses ongoing at the data cutoff and eight of the 15 responders in remission for at least 12 months, can you elaborate on the importance of these findings for the long-term management of melanoma patients?

High rates of grade 3 or above treatment-emergent adverse events were observed in the trial. How do these safety concerns compare to those of existing treatments, and what strategies might be employed to manage these side effects effectively?

Considering the efficacy and side effects observed, what impact do you believe the Lifileucel and Pembrolizumab combination will have on the overall quality of life for patients undergoing treatment for advanced melanoma?

In light of BMY's triplet regimen results in the RELATIVITY-048 trial, how does the doublet of Lifileucel and Pembrolizumab position itself in terms of efficacy and safety? Are there specific patient populations that might benefit more from one approach over the other?

Given the promising results from the IOV-COM-202 trial, what are the next steps for Iovance in seeking regulatory approval for the Lifileucel and Pembrolizumab combination? How might these results influence the decision-making process of regulatory bodies?

How do the 'paradigm-changing' response rates observed in the IOV-COM-202 trial reflect the advancements in immunotherapy for melanoma? What potential does this combination therapy have to redefine treatment protocols for advanced melanoma?

What are the key areas of future research that should be explored based on the outcomes of the IOV-COM-202 trial? How can these findings inform the development of next-generation therapies for melanoma and potentially other types of cancer?